Form D · Biotechnology
Strand Therapeutics Inc.
Boston, MA · CIK 0001778475
Offering snapshot reported Mar 17, 2026 · SEC filing
- Reported sold
- $108M Offering amount: $120M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 23, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 17, 2026 | Initial | $108,099,927 | No comparison | 10 | SEC filing |
| Jul 27, 2021 | Initial | $52,143,967 | No comparison | Not reported | SEC filing |
| Jun 7, 2019 | Initial | $5,886,624 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-576809
Source: Form D, filed Mar 17, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ala Alenazi | Director |
| Jacob Becraft | Director, Executive, Promoter |
| Jory Bell | Director |
| Pegah Ebrahimi | Director |
| Jeb Keiper | Director |
| Tasuku Kitada | Director, Executive, Promoter |
| Samta Kundu | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
20 Overland Street Suite A
Boston, MA, 02215
Boston, MA, 02215